

Check for updates

USP8 positively regulates hepatocellular carcinoma tumorigenesis and confers ferroptosis resistance through β-catenin stabilization

Jianing Tang^{1,2}, Guo Long^{1,2}, Liang Xiao^{1,2™} and Ledu Zhou^{1,2™}

© The Author(s) 2023

Hepatocellular carcinoma (HCC) is the most common type of primary hepatic carcinoma, which is a growing public health problem worldwide. One of the main genetic alterations in HCC is the deregulated Wnt/ β -catenin signaling, activation of β -catenin is associated with the progression of HCC. In the present study, we aimed to identify novel modulators in controlling β -catenin ubiquitination and stability. USP8 was overexpressed in HCC tissues and correlated with β -catenin protein level. High expression of USP8 indicated poor prognosis of HCC patients. USP8 depletion significantly decreased β -catenin protein level, β -catenin target genes expression and TOP-luciferase activity in HCC cells. Further mechanistic study revealed that the USP domain of USP8 interacted with the ARM domain of β -catenin. USP8 depletion inhibited the proliferation, invasion and stemness of HCC cells and conferred ferroptosis resistance, which effects could be further rescued by β -catenin overexpression. In addition, the USP8 inhibitor DUB-IN-3 inhibited the aggressive phenotype and promoted ferroptosis of HCC cells through degradation of β -catenin. High expression of USP8 promoted the progression and inhibited ferroptosis of HCC. Targeting the USP8 may serve as a promising strategy for patients with HCC.

Cell Death and Disease (2023)14:360; https://doi.org/10.1038/s41419-023-05747-7

INTRODUCTION

Liver cancer is one of the most urgent public health problems worldwide, which is the sixth most common neoplasm and is the fourth leading cause of cancer-related deaths in all tumors worldwide [1]. Hepatocellular carcinoma (HCC) originates predominantly from hepatocytes, it is the most common histological type of primary hepatic carcinoma, accounting for approximately 90% of primary liver cancers. HCC is known as its high malignance, rapid progression, high metastatic potency, easy recurrence, poor clinical outcomes and is usually indetectable [2]. Despite the developments in major clinical interventions, including surgery, transplantation, chemotherapy, radiotherapy, drug-targeted therapy, and immunotherapy. The advanced stage of HCC is still a therapeutic challenge, and the overall 5-year survival rate of patients with HCC is less than 20% [3–5]. Therefore, it is an urgent need to identify the novel molecular markers and develop effective approaches to treat patients with HCC.

Wnt/ β -catenin pathway is a highly conserved pathway that mainly controls cell proliferation. The activation of Wnt/ β -catenin pathway is associated with haematopoietic system development, hair follicle renewal, liver metabolism and regeneration, lung tissue repair and metabolism, and the maturation of osteoblast [6-9]. This pathway comprises the following segments: the extracellular signal; trans-membraned segment; cytoplasmic compounds including glycogen synthase kinase 3 β (Gsk3β), adenomatous polyposis coli (Apc), Axin/ conductin, casein kinase1a (CK1a), and disheveled (Dvl in mammals and Dsh in drosophila); the nuclear segment mainly contains β -catenin and TCF/LEF family members [10]. The activation of Wnt/ β -catenin pathway is mediated by the binding of extracellular Wnt ligands to membrane receptors through autocrine/paracrine methods. β-catenin functions as the ultimate effector of Wnt/ β -catenin pathway [11, 12]. After receiving the upstream activation signals, intracellular β-catenin is rapidly accumulated. Then β -catenin is trans-localized into the nucleus and binds to TCF/LEF family members to drive transcription of Wnt/β-catenin target genes involved in cell survival, differentiation, proliferation, and migration [13].

At the off state of Wnt/ β -catenin signalling pathway, β -catenin binds to the cytoplasmic sides of cadherin and a degradation complex (DC) comprising APC, AXIN, CK1 and GSK3 protein is formed. β -catenin is captured and phosphorylated by DC, thus activating the ubiquitin proteasome-mediated degradation of β -catenin and keep the low level of free β -catenin in the cytoplasm [14]. Abnormal activation of the Wnt/ β -catenin

Received: 25 October 2022 Revised: 14 March 2023 Accepted: 16 March 2023 Published online: 13 June 2023

¹Department of Liver Surgery, Xiangya Hospital, Central South University, Changsha 410008 Hunan, China. ²National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China. ^{See}email: xiaoliangrick@csu.edu.cn; zhould@csu.edu.cn Edited by Dr Angelo Peschiaroli